151 related articles for article (PubMed ID: 24749658)
1. First report of ipilimumab-induced Grover disease.
Munoz J; Guillot B; Girard C; Dereure O; Du-Thanh A
Br J Dermatol; 2014 Nov; 171(5):1236-7. PubMed ID: 24749658
[No Abstract] [Full Text] [Related]
2. Unusual complication of vemurafenib treatment of metastatic melanoma: exacerbation of acantholytic dyskeratosis complicated by Kaposi varicelliform eruption.
Gupta M; Huang V; Linette G; Cornelius L
Arch Dermatol; 2012 Aug; 148(8):966-8. PubMed ID: 22911209
[No Abstract] [Full Text] [Related]
3. [Grover's-like drug eruption under anti-PD-1 therapy for metastatic melanoma].
Amini-Adle M; Balme B; Dalle S
Ann Dermatol Venereol; 2018 Dec; 145(12):802-803. PubMed ID: 30415933
[No Abstract] [Full Text] [Related]
4. Vemurafenib sensitivity skin reaction after ipilimumab.
Harding JJ; Pulitzer M; Chapman PB
N Engl J Med; 2012 Mar; 366(9):866-8. PubMed ID: 22375995
[No Abstract] [Full Text] [Related]
5. [Acantholytic dermatosis in patients treated by vemurafenib: 2 cases].
Sabatier-Vincent M; Charles J; Pinel N; Challende I; Claeys A; Leccia MT
Ann Dermatol Venereol; 2014 Nov; 141(11):689-93. PubMed ID: 25442474
[TBL] [Abstract][Full Text] [Related]
6. Suprabasal acantholytic dermatologic toxicities associated checkpoint inhibitor therapy: A spectrum of immune reactions from paraneoplastic pemphigus-like to Grover-like lesions.
Chen WS; Tetzlaff MT; Diwan H; Jahan-Tigh R; Diab A; Nelson K; Glitza IC; Kaunitz GJ; Johnson D; Torres-Cabala C; Pacha O; Taube JM; Maloney K; Prieto VG; Curry JL
J Cutan Pathol; 2018 Oct; 45(10):764-773. PubMed ID: 29943453
[TBL] [Abstract][Full Text] [Related]
7. Ipilimumab-associated Sweet syndrome in a melanoma patient.
Gormley R; Wanat K; Elenitsas R; Giles J; McGettigan S; Schuchter L; Takeshita J
J Am Acad Dermatol; 2014 Nov; 71(5):e211-3. PubMed ID: 25437997
[No Abstract] [Full Text] [Related]
8. Neutrophilic disease of the skin and intestines after ipilimumab treatment for malignant melanoma - simultaneous occurrence of pyoderma gangrenosum and colitis.
Rudolph BM; Staib F; Von Stebut E; Hainz M; Grabbe S; Loquai C
Eur J Dermatol; 2014; 24(2):268-9. PubMed ID: 24721740
[No Abstract] [Full Text] [Related]
9. Grover Disease Associated With Chemotherapy: Review of Potential Pathophysiology, Current Treatments, and Future Directions.
Beer J; Rosenbach M
J Drugs Dermatol; 2020 Nov; 19(11):1056-1064. PubMed ID: 33196735
[TBL] [Abstract][Full Text] [Related]
10. Erythema multiforme major in a patient with metastatic melanoma treated with nivolumab.
Sundaresan S; Nguyen KT; Nelson KC; Ivan D; Patel AB
Dermatol Online J; 2017 Sep; 23(9):. PubMed ID: 29469720
[TBL] [Abstract][Full Text] [Related]
11. Grover disease (transient acantholytic dermatosis) induced by anastrozole.
Crockett JS; Burkemper NM
Cutis; 2011 Oct; 88(4):175-7. PubMed ID: 22106724
[TBL] [Abstract][Full Text] [Related]
12. Role of Immune Status in Chemotherapy-Induced Transient Acantholytic Dermatosis.
Auh SL; Polcari I; Petronic-Rosic V; Sethi A
Skinmed; 2017; 15(6):483-484. PubMed ID: 29282194
[TBL] [Abstract][Full Text] [Related]
13. Histopathological aspects of cutaneous erythematous-papular eruptions induced by immune checkpoint inhibitors for the treatment of metastatic melanoma.
Perret RE; Josselin N; Knol AC; Khammari A; Cassecuel J; Peuvrel L; Dreno B;
Int J Dermatol; 2017 May; 56(5):527-533. PubMed ID: 28188628
[TBL] [Abstract][Full Text] [Related]
14. Intertriginous and follicular eruption to anticytotoxic T-lymphocyte antigen 4 monoclonal antibody.
Lim JL; Dahiya M; Burgin S
J Am Acad Dermatol; 2008 Aug; 59(2 Suppl 1):S60-1. PubMed ID: 18625394
[No Abstract] [Full Text] [Related]
15. Enterocolitis in a patient being treated with ipilimumab for metastatic melanoma.
Koch C; Paetzold S; Trojan J
Gastroenterology; 2012 Aug; 143(2):298, 504, 505. PubMed ID: 22709738
[No Abstract] [Full Text] [Related]
16. Grover disease may result from the impairment of keratinocytic cholinergic receptors.
Paslin D
J Am Acad Dermatol; 2012 Feb; 66(2):332-3. PubMed ID: 22243730
[No Abstract] [Full Text] [Related]
17. Posterior reversible encephalopathy syndrome during ipilimumab therapy for malignant melanoma.
Maur M; Tomasello C; Frassoldati A; Dieci MV; Barbieri E; Conte P
J Clin Oncol; 2012 Feb; 30(6):e76-8. PubMed ID: 22203769
[No Abstract] [Full Text] [Related]
18. Nursing management of patients with metastatic melanoma receiving ipilimumab.
Bryce J; Passoni C
Oncol Nurs Forum; 2013 May; 40(3):215-8. PubMed ID: 23615135
[No Abstract] [Full Text] [Related]
19. [Pityriasis rubra pilaris with focal acantholytic dyskeratosis during treatment with imiquimod 5% cream].
Gómez-Moyano E; Crespo-Erchiga A; Vera Casaño A; Sanz Trelles A
Actas Dermosifiliogr; 2010 Dec; 101(10):898-900. PubMed ID: 21159271
[No Abstract] [Full Text] [Related]
20. Acantholytic dyskeratotic acanthoma: a possible skin adverse event of vemurafenib treatment.
Komori T; Otsuka A; Kaku Y; Honda T; Kabashima K
J Eur Acad Dermatol Venereol; 2017 Oct; 31(10):e474-e475. PubMed ID: 28426905
[No Abstract] [Full Text] [Related]
[Next] [New Search]
